Lucjan Wyrwicz
A5054846836- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Esophageal Cancer Research and Treatment
- Colorectal Cancer Surgical Treatments
- Gastrointestinal Tumor Research and Treatment
- Pancreatic and Hepatic Oncology Research
- Colorectal and Anal Carcinomas
- Genetic factors in colorectal cancer
- Hepatocellular Carcinoma Treatment and Prognosis
- RNA and protein synthesis mechanisms
- Lung Cancer Treatments and Mutations
- Cancer Treatment and Pharmacology
- Multiple and Secondary Primary Cancers
- Metastasis and carcinoma case studies
- RNA modifications and cancer
- RNA Research and Splicing
- Economic and Financial Impacts of Cancer
- Herpesvirus Infections and Treatments
- Protein Structure and Dynamics
- Machine Learning in Bioinformatics
- Cytomegalovirus and herpesvirus research
- Intraperitoneal and Appendiceal Malignancies
- Liver Disease Diagnosis and Treatment
- Cancer Genomics and Diagnostics
The Maria Sklodowska-Curie National Research Institute of Oncology
2016-2025
Centrum Onkologii
2014-2024
European Organisation for Research and Treatment of Cancer
2021-2022
National Institute of Oncology
2020
Polskie Towarzystwo Gastroenterologii
2015
BioInfoBank Institute
2003-2011
Pomeranian Medical University
2002-2011
Gdańsk Medical University
2009
Adam Mickiewicz University in Poznań
2004-2005
International Institute of Molecular and Cell Biology
2002
Diatoms, a type of microscopic marine and freshwater alga, dominate the oceans are responsible for about fifth primary productivity on Earth. The complete genome sequence Phaeodactylum tricornutum is reported in this issue, second diatom to be sequenced. Comparisons with Thalassiosira pseudonana, first, reveal that hundreds genes have been acquired by gene transfer from bacteria — or vice versa. Gene appears common during evolution, creating unorthodox combinations including some plants...
<h3>Importance</h3> Safe and effective therapies for untreated, advanced gastric/gastroesophageal junction (G/GEJ) cancer remain an unmet need. <h3>Objective</h3> To evaluate the antitumor activity of pembrolizumab, pembrolizumab plus chemotherapy, or chemotherapy alone in patients with G/GEJ programmed cell death ligand 1 (PD-L1) combined positive score (CPS) greater. <h3>Design, Setting, Participants</h3> The phase 3 KEYNOTE-062 randomized, controlled, partially blinded interventional...
BackgroundThere currently are no internationally recognised treatment guidelines for patients with advanced gastric cancer/gastro-oesophageal junction cancer (GC/GEJC) in whom two prior lines of therapy have failed. The randomised, phase III JAVELIN Gastric 300 trial compared avelumab versus physician's choice chemotherapy as third-line GC/GEJC.Patients and methodsPatients unresectable, recurrent, locally advanced, or metastatic GC/GEJC were recruited at 147 sites globally. All randomised to...
First-line chemotherapy for advanced esophageal squamous-cell carcinoma results in poor outcomes. The monoclonal antibody nivolumab has shown an overall survival benefit over previously treated patients with carcinoma.In this open-label, phase 3 trial, we randomly assigned adults untreated, unresectable advanced, recurrent, or metastatic a 1:1:1 ratio to receive plus chemotherapy, the ipilimumab, chemotherapy. primary end points were and progression-free survival, as determined by blinded...
Abstract Herpesviridae is a large family of DNA viruses divided into three subfamilies: Alpha -, Beta - and Gammaherpesvirinae . The process herpesvirus transmission mediated by range proteins, one which glycoprotein L (gL). Based on our analysis the solved structures HSV2 EBV gH/gL complexes, we propose that Alphaherpesvirinae Betaherpesvirinae UL130 originate from chemokines. Herpes simplex virus type 2 gL human cytomegalovirus homolog (UL130) adopt novel C chemokine-like fold, while...
In a previous phase 3 trial, treatment with trifluridine-tipiracil (FTD-TPI) prolonged overall survival among patients metastatic colorectal cancer. Preliminary data from single-group and randomized 2 trials suggest that FTD-TPI in addition to bevacizumab has the potential extend survival.We randomly assigned, 1:1 ratio, adult who had received no more than two chemotherapy regimens for of advanced cancer receive plus (combination group) or alone (FTD-TPI group). The primary end point was...
JCO
Abstract Objective To evaluate the efficacy and safety of tislelizumab added to chemotherapy as first line (primary) treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma compared with placebo plus chemotherapy. Design Randomised, double blind, controlled, phase 3 study. Setting 146 medical centres across Asia, Europe, North America, between 13 December 2018 28 February 2023. Participants 1657 patients aged ≥18 years human epidermal growth factor receptor 2 negative...
This article presents a comprehensive review of large and highly diverse superfamily nucleotidyltransferase fold proteins by providing global picture about their evolutionary history, sequence-structure diversity fulfilled functional roles. Using top-of-the-line homology detection method combined with transitive searches recognition, we revised the realm these in numerous databases catalogued protein families structures, identified 10 new fold. These include hundreds previously...
<h3>Importance</h3> Acquired resistance to anti-EGFR therapy (epidermal growth factor receptor) is frequently due to<i>RAS</i>and<i>EGFR</i>extracellular domain (ECD) mutations in metastatic colorectal cancer (mCRC). Some anti-EGFR–refractory patients retain tumor EGFR dependency potentially targetable by agents such as Sym004, which a mixture of 2 nonoverlapping monoclonal antibodies targeting EGFR. <h3>Objective</h3> To determine if continuous blockade Sym004 has survival benefit....
LBA4001 Background: NIVO demonstrated superior overall survival (OS) vs chemo in previously treated patients (pts) with ESCC (ATTRACTION-3). We report OS and progression-free (PFS) from CheckMate 648, the first global phase III study to evaluate both an immuno-oncology (I-O)/chemo combination I-O/I-O advanced ESCC. Methods: Adults untreated, unresectable advanced, recurrent or metastatic were enrolled regardless of tumor cell PD-L1 expression. Pts randomized (240 mg Q2W) + (fluorouracil...
<h3>Background</h3> We report phase 1b data from patients enrolled in the JAVELIN Solid Tumor clinical trial (NCT01772004) with unresectable stage IIIC or IV melanoma that had progressed after ≥1 line of therapy for metastatic disease. <h3>Patients and methods</h3> Patients received avelumab (10 mg/kg)—a human anti–PD-L1 antibody. Assessments included objective response rate (ORR), progression-free survival (PFS), overall (OS), safety. <h3>Results</h3> As December 31, 2016, 51 were treated...
<h3>Background</h3> We evaluated the antitumor activity and safety of avelumab, a human anti–PD-L1 IgG1 antibody, as first-line switch-maintenance (1 L-mn) or second-line (2 L) treatment in patients with advanced gastric/gastroesophageal cancer (GC/GEJC) previously treated chemotherapy. <h3>Methods</h3> In phase 1b expansion cohort, without disease progression following chemotherapy for GC/GEJC received avelumab 10 mg/kg intravenously every 2 weeks. Endpoints included best overall response,...